Physician profile
Jon Christopher Gibbs
NPI 1700896156
$1,481.60
in general payments reported to CMS, 2019-2025
21 companies · $24.33 in 2025
The $24.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $159 · 2021: $36.92 · 2022: $338 · 2023: $191 · 2024: $221 · 2025: $24.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $143.28 | 2023 | Portfolio |
| Melinta Therapeutics, LLC | $136.10 | 2021-2024 | Kimyrsa |
| Intuitive Surgical, INC. | $128.67 | 2022 | |
| Portola Pharmaceuticals, LLC | $121.82 | 2019 | |
| Astellas Pharma US INC | $109.05 | 2020 | |
| Abiomed | $108.72 | 2024 | Impella |
| Acelrx Pharmaceuticals, INC. | $101.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.84 | 2019 | |
| Heraeus Medical, LLC. | $96.00 | 2022 | |
| Tetraphase Pharmaceuticals, INC. | $90.01 | 2019 | |
| Stryker Corporation | $87.63 | 2022-2025 | Na |
| E.R. Squibb & Sons, L.L.C. | $63.00 | 2019-2022 | |
| Polynovo North America LLC | $47.49 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.96 | 2019 | |
| Resmed Corp | $32.22 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $26.92 | 2019 | |
| Glaxosmithkline, LLC. | $21.00 | 2020 | |
| Lilly USA, LLC | $15.43 | 2019 | |
| Axonics, INC. | $13.02 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Gibbs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.